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cancer treatment ranges from €10,251 to €13,934). The national
ICER was €26,361 per QALY, but the net cost per subject vac-
cinated differed across regions impacting the affordability to
vaccinate multiple cohorts 12-years/catch-up to 16-years. CON-
CLUSIONS: National analyses, using national ‘average’ data, are
the necessary starting point for the evaluation of new health
technologies, addressing centralized regulatory agency require-
ments. However, in the Italian scenario, characterized by decen-
tralization and local autonomy, a further level of detail is
essential in order to describe the regional impact to budget
holders thereby better informing local decision makers and facili-
tating the uptake of cost-effective health care interventions.
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OBJECTIVES: Capecitabine’s mCRC licence was recently
extended supporting its use in combination therapy. This study
evaluated the cost effectiveness of replacing FOLFOX, with
XELOX. METHODS: Based on results from phase 3 trials,
demonstrating that XELOX is non-inferior to FOLFOX4
(NO16966 1st line; NO16967 2nd line), a cost minimisation
analysis was performed evaluating incremental costs from the
start of treatment until disease progression. Dose, treatment dura-
tion, adverse event frequency and the probability of central venous
access device (CVAD) replacement were taken directly from the
NO16966/7 trials. Drug costs were based on the UK list price.
Administration, pharmacy and adverse event costs were taken
from NHS reference costs 2005/6, the literature, and previous
technology appraisals. Clinical practice assumptions were: 10%
and 100% of XELOX and FOLFOX patients receive a CVAD
respectively; 25% of 5FU infusions require an overnight stay in
hospital, the remaining 75% use an ambulatory pump at home;
30% of patients receive hospital funded transport. Uncertainty
was explored via one-way sensitivity analysis and a scenario of
FOLFOX6 being replaced in 1st line (ceteris paribus) was also
evaluated. RESULTS: Per patient, replacing FOLFOX4 with
XELOX, saved (1st/2nd line) £578/£498 drug acquisition, £773/
£341 CVAD placement, £8078/£5561 pharmacy and administra-
tion, and £173/£17 adverse event costs. Total savings were £9611
and £6405 1st and 2nd line respectively. In all of the scenarios
evaluated in the sensitivity analysis XELOX was cost saving by
more than £8636 per patient 1st line, and £5702 2nd line, com-
pared to FOLFOX4. XELOX remained cost saving (~£6500)
when compared to FOLFOX6. CONCLUSIONS: Replacing
FOLFOX with XELOX offers the NHS considerable savings in
terms of administration and pharmacy, and to a lesser extent drug
acquisition costs, with equivalent efﬁcacy. Additionally patients
may prefer XELOX due to the reduction in hospital administra-
tion visits and probability of requiring a CVAD.
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OBJECTIVES: To evaluate the effect of a nurse telephone
follow-up as a strategy for improving therapeutic adherence
among outpatients with schizophrenia. METHODS: A 16–week,
open, multicentre, randomised controlled trial. Patients fulﬁlled
criteria for schizophrenia (DSM-IV TR criteria). To be eligible,
patients had to be ambulatory in treatment with an oral antip-
sychotic agent. Participants were randomised to receive monthly
telephone calls from a nurse of mental health center or standard
clinical follow-up. Phone calls were performed at weeks 4, 8, and
12 in the intervention arm. The calls consisted of a brief inter-
view to assess treatment compliance and Drug Attitude Inventory
(DAI-10). A compliance with60% of doses was used to classify
patients as compliant. Primary endpoint was the difference in the
percentage of compliant patients after nurse telephone follow-up
versus control group at week 16. Secondary endpoints included
socio-demographic data, past mental health diagnosis, Clinical
Global Impression-Schizophrenia (CGI-SCH), DAI-10, and
Euroqol EQ-5D. Study protocol was approved by a local Ethical
Committee and all patients provided written informed consent.
RESULTS: A total of 865 patients were studied, 65% men. Mean
age: 40.08 years (SD = 11.6). Baseline socio-demographic and
main clinical characteristics were similar between both groups:
mean time from diagnosis: 13.08 years (SD = 9.5), mean number
of hospitalisations in the last 5 years: 2.23 (SD = 2.7), mean time
from last relapse: 3.1 years (SD = 3.9). A total of 88.2% (374)
patients in the intervention arm were compliant vs 90.0% (397)
in control arm. At baseline, mean CGI-SCH, DAI-10, and
EQ-5D scores were similar in both groups. At week 16, 410
(96.7%) patients fulﬁlled compliance criteria in the intervention
group vs 402 (91.1%) in the control group. An absolute differ-
ence of 5.5% was found between groups (CI95%, 2.3–8.6%;
p = 0.0007); OR 3.57 (CI95%, 1.81–7.04). Mean global CGI-
SCH and DAI-10 scores were better in the intervention arm: 3.07
vs 3.25 p = 0.009; 6.05 vs 5.19 p < 0.0001, respectively. CON-
CLUSIONS: Despite a high baseline rate of compliance of the
studied population, nurse telephone intervention increased
antipsychotic adherence. A nurse telephone follow-up could be a
complementary strategy to improve therapeutic adherence in
schizophrenic patients.
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OBJECTIVES: To assess adherence, persistence, costs and
Health-Related-Quality-of-Life (HRQoL) in patients undergoing
A344 Abstracts
antipsychotic treatment. METHODS: A naturalistic, prospective
cohort study, named COMETA, was conducted in 2006–2008.
Subjects aged 18–40 years, diagnosed with schizophrenia or
schizophreniform disorder 10 years before, were enrolled in 86
psychiatric centres throughout Italy and followed-up for a target
period of 52 weeks. Data on socio-demographic, clinical status,
adherence, HRQoL, resources consumption were collected (soci-
etal perspective adopted to estimate costs). RESULTS: A total of
637 valid patients (mean  SD age = 30.9  5.9, 65.0% male)
were enrolled and followed-up to 63.9 weeks. At enrolment,
the Positive-and-Negative-Syndrome-Scale (PANSS) mean  SD
score was 86.6  27.4, the Clinical-Global-Impression-Severity
(CGI-S) mean  SD score was 4.3  1.1, the Global-Assessment-
of-Functioning (GAF) mean  SD score was 54.1  13.8. With
EQ-5D 68.8% of patients reported moderate/severe anxiety/
depression, 52.7% reported problems with usual activities,
37.8% reported pain/discomfort, 21.4% had problems with
mobility, 16.7% problems with self-care, VAS mean  SD =
63.5  17.9. SF-36-PCS mean  SD = 47.59.3, SF-36-MCS
mean  SD = 39.0  9.6. During 90 days before enrolment,
1.9% patients did not take any antipsychotic drug, while 27%
took 2–5 different drugs. The Drug-Inventory-Attitude (DAI-30)
mean  SD score, assessing the patients’ subjective attitude
toward antipsychotic therapy, was 43.4  5.0. Physicians
reported that 71.1% patients always took the prescribed antipsy-
chotic therapy. Eighty-ﬁve percent of medical costs occurring 90
days before enrolment were: €114.00/patient-month for psycho-
therapy, €105.75/patient-month for hospitalizations (€89.49€ for
relapse), €86.37/patient-month for antipsychotics, €13.74 for
concomitant drugs. The patients persisted to treatment with oral
typical, atypical or long acting/depot drugs on average 53.9
weeks. During the follow-up, psychotherapy cost was 100.03€/
patient-month, hospitalizations cost €57.26/patient-month,
antipsychotic drug therapy cost €126.10, concomitant therapy
cost €16.47/patient-month. At the end of follow-up the patients’
clinical status, HRQoL and attitude toward treatment was on
average improved. CONCLUSIONS: Increase of adherence and
persistence toward antipsychotic treatment is a primary goal to be
reached for the improvement of well being in schizophrenic
patients and for making more efﬁcient investments.
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Almost 75% of schizophrenia patients do not comply with their
prescribed treatment leading to high relapse rates. Patient cen-
tered care (PCC) incorporates patient priorities into treatment
decisions, and has been proposed as a means to enhance compli-
ance and improve health outcomes among patients with schizo-
phrenia. PCC requires that patient objectives, priorities, and
desired outcomes be quantiﬁed and incorporated into treatment
decisions. Patient priorities for the treatment of schizophrenia
have not been evaluated. OBJECTIVES: To identify the spectrum
of patient objectives and priorities associated with the treatment
of schizophrenia. METHODS: Data was collected across
Germany in two stages: focus groups (n = 30) and individual
in-depth patient interviews (n = 25). Patients were eligible for
inclusion if they had been diagnosed with schizophrenia had
undergone treatment with an antipsychotic medication for at
least one year and, their disease was stable. The focus group
interviews were used to identify key attributes. These key
attributes were then quantiﬁed by a card sort exercise in indi-
vidual interviews. Results were analyzed using modiﬁed version
of the Borda Count on a scale from 0 to 100 and validated by
triangulation methods. RESULTS: Focus group interviews iden-
tiﬁed 13 objectives of primary importance to the patient. The
card sorting exercise during the in-depth interviews yielded the
top ﬁve attributes: therapeutic minimization of symptoms
(75.43), ability to concentrate/ think clearly (75.34), ability to
participate in social activities (69.93), alliance with physician
(66.19), and avoiding acute symptoms (62.62). The scores
ranged from 29.42 to 74.43 out of a possible 100 points. CON-
CLUSIONS: Traditionally, treatment for schizophrenia has
focused on remission of symptoms; however, patient’s top pri-
orities involve the processes of care. Addressing patient’s priori-
ties and improving the entire treatment pathway will likely lead
to increased compliance with treatments and ultimately improve
clinical outcomes.
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OBJECTIVES: The purpose of this study was to estimate the
direct cost of treating patients with schizophrenia in Greece,
based on 12-month retrospective data collected at baseline from
e-STAR. METHODS: e-STAR is an ongoing, international, pro-
spective, observational study of clinical and economic outcomes
in schizophrenic patients who switch to a new antipsychotic.
e-STAR captures real-life data both in the inpatient and outpa-
tient settings based on a systemic data collection form via a
secured web-based system. At baseline, psychiatric-related
resource utilisation, such as hospitalisation, community care,
visits to health care professionals, diagnostic procedures and
use of medication, was retrospectively collected for the previous
12 months. Unit costs were derived from published literature,
price lists of social insurance funds, the Greek NHS and the
private sector. RESULTS: Data from 798 patients (57.5% male)
who were enrolled in e-STAR in Greece and diagnosed with
schizophrenia were analysed. The mean age of the study popu-
lation was 39.5 years and the mean time since diagnosis was 12.4
years. Analysis of resource utilization data indicated that total
length of stay in public psychiatric hospitals was 2.7 times higher
than that in private clinics. Outpatient care mainly consisted of
visits to psychiatrists, whereas visits to other relevant health care
professionals were very low. Finally, the total annual cost per
patient with schizophrenia was estimated at €3729, of which
64.5% referred to hospital and community care, 18.5% to out-
patient care, 6.0% to diagnostic procedures and only 11.0% to
medication. CONCLUSIONS: This is the ﬁrst time that large-
scale Greek real-life data are used in the ﬁeld of the economics of
schizophrenia in Greece. The results of this study are in general
agreement with ﬁndings of previous studies conducted in Greece
and Europe. Further research needs to be undertaken in this ﬁeld
when long-term prospective data become available from e-STAR.
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